Evidence map›Paper›PMID 32441462›Full record

ArticleClinical and translational science2020

Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.

Dan Hartman, Steven Kern, Fran Brown, Suzanne K Minton, Craig R Rayner

Abstract read
In one paragraph

Article in Clinical and translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dan HartmanBill & Melinda Gates Foundation, Seattle, Washington, USA.
Steven KernBill & Melinda Gates Foundation, Seattle, Washington, USA.
Fran BrownCertara Inc., Princeton, New Jersey, USA.
Suzanne K MintonCertara Inc., Princeton, New Jersey, USA.
Craig R RaynerCertara Inc., Princeton, New Jersey, USA.

Funding

Bill & Melinda Gates Foundation
6 · The paper itself

Abstract

The global response to finding therapeutics for coronavirus disease 2019 (COVID-19) is chaotic even if well intentioned. There is an opportunity, but more importantly, an obligation for the global clinical and quantitative pharmacology community to come together and use our state-of-the-art tools and expertise to help society accelerate therapeutics to fight COVID-19. This brief commentary is a call to action and highlights how the global pharmacology community should contribute to the COVID-19 pandemic and prepare for future pandemics.

Indexed as

Antiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19Dose-Response Relationship, DrugDrug ApprovalDrug DevelopmentDrug DiscoveryDrug Dosage CalculationsHumansPandemicsPatient SafetyPharmacology, ClinicalPneumonia, ViralSARS-CoV-2Time FactorsAntiviral Agents

Identifiers

PMID32441462
PMCPMC7280646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.